Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | PDE4A | P27815 | 2/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9881233 | 0.90 | CYP1A2 (0.61) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL4743128 | 0.90 | MAPT (0.55) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL12682304 | 0.90 | MAPT (0.52) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL9881243 | 0.90 | MAPT (0.52) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL14105450 | 0.87 | ABCG2 (0.57) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL11891893 | 0.87 | MAPT (0.49) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL4783849 | 0.87 | MAPT (0.49) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL11990373 | 0.79 | MAPT (0.43) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 | |
| SCHEMBL14104174 | 0.78 | HTT (0.60) | MAPTL3MBTL1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL14104172 | 0.77 | ABCG2 (0.49) | MAPTL3MBTL1ABCG2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-9005605-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8926963-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8900571-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8894992-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8889123-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8883139-B2 | Compositions and soft tissue replacement methods | ALLERGAN INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140179752-A1 | METHODS OF TREATING SOFT TISSUE DEFECTS | ALLERGAN, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8741281-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-20120269777-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120219627-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120213853-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120213852-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120189589-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189591-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189708-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120189590-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2008092860-A1 | BICYCLIC DERIVATIVES AS EP4 AGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179752-A1 | METHODS OF TREATING SOFT TISSUE DEFECTS | TNNC1, COL2A1, ALPP | MAPT 4855/4885L3MBTL1 448/4885ABCG2 4100/4885 |
| US-20120189591-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120213852-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120189590-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120189708-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120189589-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120219627-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120269777-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
| US-20120213853-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | MATR3, COL2A1, TNNC1 | MAPT 4801/4885L3MBTL1 584/4885ABCG2 3198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.